Abbott Laboratories (ABT)

64.72
NYSE : Health Technology
Prev Close 64.16
Day Low/High 64.03 / 64.92
52 Wk Low/High 48.58 / 65.90
Avg Volume 4.77M
Exchange NYSE
Shares Outstanding 1.75B
Market Cap 112.56B
EPS 0.30
P/E Ratio 139.48
Div & Yield 1.12 (1.74%)

Latest News

Tariffs, Trade, and Now, Turkey: Cramer's 'Mad Money' Recap (Monday 8/13/18)

Tariffs, Trade, and Now, Turkey: Cramer's 'Mad Money' Recap (Monday 8/13/18)

Jim Cramer says investors should turn this Turkey-induced selloff into a buying opportunity.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Weekly Roundup

Markets end the week on a sour note.

Weekly Roundup

Markets edged higher in what was a busy week from both a political and economic perspective.

Abbott Expands Its Directional Deep Brain Stimulation Therapy By Offering New MR-Conditional Labeling

Abbott Expands Its Directional Deep Brain Stimulation Therapy By Offering New MR-Conditional Labeling

- FDA approval of new software upgrade for Abbott's deep brain stimulation therapy enables advanced, patient-centric features for people living with Parkinson's disease and essential tremor

When Sellers Walk Away: Cramer's 'Mad Money' Recap (Tuesday 7/31/18)

When Sellers Walk Away: Cramer's 'Mad Money' Recap (Tuesday 7/31/18)

Jim Cramer says the tide of selling eventually ebbs, and when it does, stocks rally.

IDEXX Labs, Evolent Health, Triton: 'Mad Money' Lightning Round

IDEXX Labs, Evolent Health, Triton: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at IDEXX Labs, Evolent Health, Triton, Western Gas Partners, Zimmer Biomet and more.

Sector Rotation Is Powerful: This Tech Hit Is a Great Trade

Sector Rotation Is Powerful: This Tech Hit Is a Great Trade

As hedge funds are forced to unwind tech positions, here is how to play the rotation.

Weekly Roundup

An earnings heavy week also included progress on reducing trade tensions.

Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved In U.S.

Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved In U.S.

- ALLOWS USERS TO WEAR THE SENSOR FOR UP TO 14 DAYS WITH HIGH ACCURACY

Abbott Begins U.S. Pivotal Trial For The Tendyne Mitral Valve Replacement System To Treat Patients With Heart Valve Disease

Abbott Begins U.S. Pivotal Trial For The Tendyne Mitral Valve Replacement System To Treat Patients With Heart Valve Disease

- Investigational Tendyne device is first and only repositionable and fully retrievable mitral valve replacement

Be On Guard: Cramer's 'Mad Money' Recap (Monday 7/23/18)

Be On Guard: Cramer's 'Mad Money' Recap (Monday 7/23/18)

Jim Cramer says tariffs and trade could be tough on some stocks, but he's optimistic about earnings season.

Pullback in Abbott Labs Gives Buyers Another Chance

Pullback in Abbott Labs Gives Buyers Another Chance

Our latest analysis and strategy on ABT shares.

Last Week's Portfolio Changes

We raised our price targets on four positions after their latest earnings reports.

Jim Cramer: Trade Wars and Tariffs May Soon Be Baked Into Pricing

Jim Cramer: Trade Wars and Tariffs May Soon Be Baked Into Pricing

Earnings have been strong, and analysts will soon start to concentrate more on actual weakness than shadow-boxing weakness.

Markets Rise, Ignoring Trump as Earnings Reports Begin

Stocks moved up this week as earnings season got underway and investors shrugged off more trade war threats from President Trump.

Three Key Takeaways From Healthcare Earnings Season

Three Key Takeaways From Healthcare Earnings Season

Drug pricing remains front and center as healthcare companies start reporting quarterly results.

Market Loves Fintech: Cramer's 'Mad Money' Recap (Thursday 7/19/18)

Market Loves Fintech: Cramer's 'Mad Money' Recap (Thursday 7/19/18)

Jim Cramer says financial payment companies are the most beloved in the market right now. He explains digitized payment companies. And love.

Jim's Daily Rundown

Jim discusses his interview with Larry Kudlow at the Delivering Alpha conference, Nucor's earnings, Danaher's earnings and announced spin, Abbott Labs, and Comcast!

Dow, S&P 500 End Higher; Nasdaq Flat

Dow, S&P 500 End Higher; Nasdaq Flat

The Dow and S&P 500 held onto modest gains at the close, while the Nasdaq ended flat following the second day of Congressional testimony from Fed Chairman Jerome Powell Wednesday.

Abbott Laboratories Gaps to the Upside in a Classic Breakout

Abbott Laboratories Gaps to the Upside in a Classic Breakout

If you are long ABT continue to hold and raise sell stop protection to a close below $59 or where the 200-day moving average line intersects.

Abbott Labs Fired on All Cylinders In the Second Quarter

The company is on track for another terrific year of double digit earnings per share growth.

Abbott Shares Rise on Second-Quarter Beat, Increased Guidance

Abbott Shares Rise on Second-Quarter Beat, Increased Guidance

The Abbott Park, Ill., healthcare company beats top- and bottom-line estimates and raises its full-year outlook for earnings.

Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon

Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon

This group is expected to post second-quarter EPS gains of 30%; here is how to trade it.

Abbott Reports Second-Quarter 2018 Results

Abbott Reports Second-Quarter 2018 Results

- Second-quarter reported sales growth of 17.0 percent; GAAP EPS from continuing operations of $0.40

Google, Morgan Stanley, IBM and Texas Instruments - 5 Things You Must Know

Google, Morgan Stanley, IBM and Texas Instruments - 5 Things You Must Know

U.S. stock futures are flat on Wednesday, following an upbeat assessment of the U.S. economy from Federal Reserve Chairman Jerome Powell; Morgan Stanley and IBM report earnings; Google faces a record $5 billion fine from the European Union.

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

In April, CEO Miles White said the healthcare company had paid down $6 billion of debt this year and expected to pay down another $2 billion by the end of 2018.

TheStreet Quant Rating: B (Buy)